PharmGen Science

PharmGen Science Debt

The Debt of PharmGen Science (004720.KS) as of Oct 9, 2026 is 17.60 B KRW. In the previous year, Debt was 19.33 B KRW — a change of -8.95% (lower).

Debt

17.60 BKRW

YoY

-8.95%

Last updated:

In 2019, PharmGen Science's total debt was 17.60 B KRW, a -8.95% change from the 19.33 B KRW total debt recorded in the previous year.

The PharmGen Science Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2014
9.53 B KRW
Jan 1, 2015
4.61 B KRW
Jan 1, 2016
10.31 B KRW
Jan 1, 2017
457.20 M KRW
Jan 1, 2018
19.33 B KRW
Jan 1, 2019
17.60 B KRW
The PharmGen Science Debt history
YEARDebtYoY
17.60 BKRW-8.95%
19.33 BKRW+4,127.94%
457.20 MKRW-95.56%
10.31 BKRW+123.66%
4.61 BKRW-51.65%
9.53 BKRW—
Access this data via the Eulerpool API
Get Free API Key

PharmGen Science Stock analysis

What does PharmGen Science do? PharmGen Science is one of the most popular companies on Eulerpool.

Debt Details

Understanding PharmGen Science's Debt Structure

PharmGen Science's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing PharmGen Science's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to PharmGen Science’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in PharmGen Science’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about PharmGen Science stock

Debt of PharmGen Science is 17.60 B KRW in 2019.

Debt of PharmGen Science changed from 19.33 B KRW to 17.60 B KRW, representing a -8.95% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt PharmGen Science since 2006 – with annual values, charts, and detailed analysis.

Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's PharmGen Science historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — PharmGen Science

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — PharmGen Science